I’m a pharmacist.
I work in a pharmacy and make $10,000-$20,000 a year, plus expenses like insurance and pharmacy equipment.
And I love it.
I like my job.
But I also love getting sick, and getting treated for it.
In fact, I can’t believe how many people I’ve seen get the flu vaccine.
And, of course, I’m just one of many in the medical profession who get tested and have their vaccine tested.
But when I hear of people getting vaccinated, I get a little uneasy.
I have to say, it’s been quite an experience.
The vaccine is one of the biggest things I’ve ever seen in my entire career.
We’ve never seen anything like this in my life, especially when it comes to vaccines.
But what I really love about the vaccine is that it’s a great vaccine.
It is a vaccine that is highly effective.
It’s also very safe.
There are no side effects, and there’s no known side effects from any of the vaccines.
And when I started working in pharmacy, we never had to worry about how we would handle our patients who had been vaccinated.
When I was younger, I was a pharmacoepidemiologist.
That was my first job, and it was a really good position to be in.
We could study every aspect of a disease.
We were able to get a very good understanding of the epidemiology of that disease.
I was also able to understand how vaccines work.
So I’m not just an expert, I also have a lot of experience in developing vaccines, which is important because I work with patients.
I have worked with patients in developing different vaccines.
I’m very good at this.
And now I’m the chief executive officer of Pharmacoepis Health Systems Inc., which is a division of the Canadian Health Sciences Centre.
And we’re very fortunate because the company is on the forefront of new vaccines.
The vaccine is safe.
We have the world’s most robust vaccine manufacturing facility.
And the manufacturing process is extremely rigorous.
I think this is one vaccine that we’re excited about.
Myself and a colleague have developed a vaccine for the flu that’s designed to kill the flu virus.
And as we develop this vaccine, we’re also testing a new way to deliver it.
We’re testing a novel vaccine that has the ability to be delivered by injection, which has a very low chance of spreading.
And it’s not as aggressive as the vaccine we have now.
So we are testing a vaccine designed to deliver the vaccine as a small capsule.
And this is a very different way to administer the vaccine.
So what that means is that, if we are successful in developing the vaccine, it will be available in the pharmacy within two weeks of its release.
And then if people who have received the vaccine are healthy and have not had any flu symptoms, then it will not be a problem.
And we have been very lucky in this vaccine.
We had a lot more people who got the vaccine than we expected, and we also had a little bit more of the flu.
And that was really helpful to us because we were able take advantage of the new environment we had.
So the other thing we were doing in that vaccine was, we developed a way to give it to people with chronic fatigue syndrome.
We found out that people who had chronic fatigue were having trouble controlling their immune system, so we started to look into that.
And at that time, we were still using a lot less antibiotics than we should be using.
So this was a very challenging time for us because, we didn’t know what the next step was going to be, and the drug development was still very slow.
So in the end, we found that we were getting around 10 percent better control with the flu vaccination.
And there were some people who were able, when we stopped the use of antibiotics, to have a significantly better response.
So the flu was still there, and you still had to be on your toes.
And even if you had a flu, you still didn’t want to be outside, you just wanted to be home with your family.
And if you were in a wheelchair or had a mobility issue, you really needed to go somewhere, because you were not going to get around.
But it was still a very tough time.
A couple of months later, we tested a vaccine we had developed.
It was a vaccine based on the DNA of the H5N1 bird flu virus, which killed the bird flu and killed some people.
And once we did that, we started getting reports of a much better response to the vaccine and to the drug.
So at that point, we thought, okay, we’ve got a vaccine candidate that we can get out of the lab.
And so, once we were in the laboratory and we were starting to get good data on how it was doing, we got the government